knowledge -WSS

knowledge

author：leisure time 2025-09-28 23:48:05 - browse：94

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Latigo launches with $135 million for Vertex

leisure time

WSS

Too many hospitalized Covid

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Drug companies' payments and gifts affect physicians' prescribing

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Scientific mystery highlights the blind spots in genomics databases

Pancreatic cancer is often deadly, but new discoveries are raising hope

Wikipedia

knowledge

focus

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Amylyx, Aurinia, and IQVIA

What does generative AI mean for health care? We asked experts

Resistance to opioid

Medicare proposal to cover medical devices draws a mixed reaction

Ebola vaccine can save some who are already sick, per new study

Bright Health sells Medicare Advantage business to Molina

Congress considering partial increase for doctor pay in Medicare

Novavax promises a turnaround & Lilly roils the obesity market

Abbott's new heart device gets FDA advisory panel nod

knowledge

Resistance to opioid

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Republican states more likely to report Covid vaccine side effects

Pancreatic cancer is often deadly, but new discoveries are raising hope

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Oral obesity drug from Viking Therapeutics hits key early target

leisure time

hotspot

leisure time

Wikipedia